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TGA anti-transglutaminase 2 antibodies 
DGP antibodies againt deamidated gliadin peptides 
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Abstract  
Coeliac disease has for a long time simply been regarded as a gluten-dependent enteropathy and a 
duodenal biopsy was required in all patients for the diagnosis. It is now accepted that autoimmunity 
against transglutaminase 2 is an earlier, more universal and more specific feature of coeliac disease 
than histologic lesions. Moreover, high serum levels of combined anti-transglutaminase 2 and anti-
endomysium antibody positivity have excellent predictive value for the presence of enteropathy 
with villous atrophy. This makes the histology evaluation of the gut no longer necessary in well 
defined symptomatic paediatric patients with compatible HLA-DQ2 and/or DQ8 background. The 
biopsy-sparing diagnostic route is not yet recommended by gastroenterologists for adults, and 
certain clinical circumstances (immunodeficiency conditions, extraintestinal manifestations, type-1 
diabetes mellitus, age less than 2 years) may require modified diagnostic approaches. Coeliac 
patients with preserved duodenal villous structure do exist and these need a more extended 
evaluation by immunologic and molecular biology tools.    
 
Introduction 
The burden of diagnosing coeliac disease (CD) is high: when made, the patient has to follow a 
gluten-free diet (GFD) for life and, when missed, exposes the patient to elevated risk of 
complications which could be avoidable. Today, the symptoms are highly variable and may be even 
absent and the most consistent finding is autoimmunity indicated by the presence of anti-
transglutaminase antibodies (TGA) accompanied in most, but not all, cases by enteropathy with 
villous atrophy. The diagnostic findings are gluten dependent and premature changes in the diet 
may interfere with the diagnosis. Nowadays, information on CD and suggestions to reduce gluten 
intake are abundant from the internet and other media, thus delays in appointments and diagnostic 
procedures may decrease diagnostic success.  
  
Evolution of diagnostic criteria 
CD was initially defined as steatorrhea on a gluten-containing diet. The first accurate diagnostic 
criteria were published in 1969 by the European Society of Paediatric Gastroenterology and 
Nutrition (ESPGAN), which were based on three histology evaluations of the small intestinal 
mucosa establishing the presence of a gluten-dependent enteropathy (severe villous atrophy at 
diagnosis, remission on a gluten-free diet and relapse after gluten provocation)1. Even after the 
recognition of disease-specific antibodies and the reduction of required biopsies in 19902, for many 
years CD has been defined, and thus simply considered, as a gluten dependent enteropathy. 
However, the most recent ESPGHAN diagnostic guidelines (2012)3 for the first time defined CD as 
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an immune-mediated systemic disorder elicited by gluten and related prolamines, occurring only in 
genetically susceptible individuals carrying the human leukocyte antigen (HLA) class II haplotypes 
-DQ2 and/or -DQ8 and characterised by the presence of a variable combination of gluten-dependent 
clinical manifestations including gastrointestinal and extra-intestinals signs and symptoms, elevated 
titers of coeliac-specific antibodies, autoantibodies against the enzyme type-2 (tissue) 
transglutaminase (TG2), endomysium and deamidated gliadin peptides (DGP) and a small intestinal 
enteropathy3.  
 
Tools for the diagnostic evaluation 
 
Antibodies 
 
Primary antibodies 
CD is an immune-mediated disorder orchestrated by DQ2 and/or DQ8-restricted gluten-specific T 
cells. These T cells recognise mostly, but not exclusively, modified gliadin peptides bearing 
deamidation pattern specific for the enzyme TG2 and provide help for antibody production upon 
gluten exposure4. Gliadin presentation to specific T cells and anti-gliadin antibody production may 
occur in many people5, but the immune response coupled with antibody production against TG2 is 
unique for CD. Gluten-dependent TGA are specific biomarkers of CD and they are predominatly of 
IgA class6, 7. Patients with selective humoral IgA deficiency (total serum IgA <0.05g/l) produce IgG 
and IgM class TGA8, 9. Recently, disease-specific epitopes of TGA have been identified and they 
show a very conservative pattern common in all CD patients10, 11 
 
TGA are produced in gut plasma cells12 and the antibodies locally bind to the TG2 autoantigen in 
the mucosa13. TGA are first accumulating in tissues expressing TG2 (gut, liver, spleen, heart, 
kidney, brain, endocrine glands, placenta) and also may appear in the circulation, duodenal juice13 
and saliva14. It is important to note that serum TGA levels reflect only the tip of an iceberg, and 
TGA can be produced and present in the patient’s body even if serum levels are low, fluctuating, or 
absent at a certain timepoint. However, seronegative CD is uncommon and in such cases special 
caution and additional tests are needed to satisfactorily confirm the CD diagnosis15.  
 
TGA antibodies can be detected from blood or other body fluids by a number of immunoassays, 
commonly by enzyme-linked immunoassay (ELISA) or radio-binding immunoassay (RIA). 
Automated systems (EliA, ImmunoCAP, BioFlash) offer easier handling, higher output and daily 
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results with a short turnaround time. Optimal results are obtained with human TG2 antigens6. 
Immunochromatographic methods with visual reading can also be used at the bedside or point of 
care (rapid tests)6. TGA have been described in a number of other autoimmune disorders, liver 
diseases, heart failure, psoriasis, childhood infections with Epstein-Barr virus (EBV)16. In contrast 
to real coeliac TGA, these other antibodies are not gluten dependent, often occur in a low 
concentration and have different epitope specificity10 and VH usage17. Despite the numerous 
publications mentioning these non-CD antibodies, well optimised tests detect nowadays most often 
real CD-associated TGA positivity, and the presence of CD must be carefully evaluated in every 
case with TGA positive (TGA+) results. The coeliac relevance of a TGA+ result can be easiest 
checked by immunofluorescent test in which the serum samples are added to frozen normal tissue 
sections containing abundant extracellular TG2 (human umbilical cord, monkey oesophagus) and 
the TG2-specific binding pattern is evaluated by microscope (endomysial antibody test, EMA). In 
other words, EMA antibodies are a special, CD-specific subgroup of TGA18. EMA+TGA+ subjects 
are thus defined as having coeliac autoimmunity19. In the EMA reaction, the TG2 protein is offered 
as a fibronectin-bound antigen and TGAs with hidden or intracellular epitopes may not bind. Non-
CD TGA antibodies generated by tissue damage or inflammation often target the intracellular TG2 
epitopes and are usually negative in the EMA test16.   
 
EMA+TGA+ serum results have very high long-term predictive value for CD20, 21. Studies in both 
children and adults showed that when TGA+ exceeds 10 times of the upper limit of normal 
(10xULN) called here EMA+TGA+High, properly processed and evaluated histology specimens 
almost invariably show crypt hyperplastic villous atrophy (Marsh III) characteristic for CD22-24 This 
high (98-100%) positive predictive value of EMA+TGA+High results has now been repeatedly 
confirmed in symptomatic patients25-30 in clinical settings, and similar data have recently emerged 
also in T1D31, family members32 and asymptomatic seropositive subjects detected by screening.33 
The positive likelihood ratio of EMA+TGA+High results is around 100-2006 and in this range the low 
pre-test probability has little or no effect any more. The definition of EMA+TGA+High is kit 
dependent. The 10xULN seems to be safe for a great number of currently available diagnostic 
tests3, but may not be appropriate for all local settings26, especially if the result calculation is not 
calibration curve based21. In such cases, the high values should be established and locally validated 
by utilizing histology as the reference test26. It is important to emphasise that villous atrophy is 
found in more than half of cases with EMA+TGA+Low results as well33, thus histology evaluation is 
clearly recommended for this group (Table1 and 2). 
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The use of antibodies against native gliadin peptides (AGA) is not recommended in the diagnosis of 
CD due the low sensitivity and low specificity of AGA results6. Antibodies against DGP have better 
specificity7, but surprisingly IgA DGP+ seems less useful than IgG DGP+ and adding DGP tests in 
TGA+ patients may result in lower specificity than using TGA+ alone.34 IgG DGP tests have been 
suggested in patients with unknown total serum IgA values or IgA deficiency, and in cases with 
malabsorption and EMA-TGA- status, especially if the patient is younger than 2 years of age. 
Unfortunately approximatively 30% of healthy infants with a familiar risk produced DGP without 
TGA shortly after gluten intake in a prospective study35 and the positivity lasted even beyond 2 
years of age.  
TGA, EMA and DGP IgA and IgG antibodies in CD patients are gluten-dependent, but they may 
decrease with different kinetics on a GFD22. It is thus important to check for gluten amounts in the 
diet when only some of these antibodies are positive and the others are negative. 
 
Secondary antibodies 
There are important inflammatory changes in the small bowel during the active phase of CD with 
increased apoptosis and tissue damage. Such changes can occur also in other organs, e.g. in the 
brain or in endocrine glands. Thus secondary antibodies against cell contituents can be generated in 
nonspecific ways. Antibodies against actin, DNA, immunoglobulins, Purkinje cells, thyreoglobulin 
or pancreatic islet cells can be found at elevated levels in active CD patients, but some may not be 
simply responsive to a GFD36. In cases with dermatitis herpetiformis (DH) antibodies reacting with 
transglutaminase 337 , in cases with neural involvement antibodies reacting with transglutaminase 6 
can be present38. These secondary antibodies may indicate specific organ damage, but they have 
only a restricted role in the diagnosis of CD itself. The serum level of anti-actin antibodies seems to 
correlate with the presence of villous atrophy29 and this information can be useful. 
    
Genetic tests 
Currently no genetic test is available to confirm the presence of CD, therefore genetic testing is only 
useful to establish a predisposition risk or help exclude CD in controversial cases. 
 
HLA-DQ alleles 
The immune reaction to gluten requires the proper presentation of peptides to T cells which can 
occur via HLA-DQ2 or -DQ8 molecules, having suitable pockets to accomodate negatively charged 
moieties of deamidated gliadins. Approximatively 30% of Caucasian normal populations carry DQ2 
or DQ8, but variations of these antigens can be present in Chinese, African-American and 
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indigeneous Australian populations as well at a lower rate39, 40. So a positive DQ2 or DQ8 result 
does not mean the person has CD, indeed he or she can be a healthy carrier. On the contrary, 
absence of both DQ2 and DQ8 makes the probability of CD very low or negligible4.    
 
The HLA-DQ surface molecules are heterodimers consisting of an alpha chain encoded by the 
DQA1 locus and a beta-chain encoded by the DQB1 locus, both highly polymorphic in humans. 
Strings of DRB1-DQA1-DQB1 molecules are usually inherited together as conserved haplotypes in 
Caucasians (Table 3), with very little recombination rate during many generations. However, some 
variations cannot be excluded giving rise to unusual haplotype combinations which can indeed 
present gliadin peptides but will not be recognised as canonical full DQ2 or DQ8 heterodimers at 
the testing. HLA-DQ testing is performed as polymerase chain reactions (PCR) amplifying alleles 
by specific primers or by evaluating haplotype-associated single nucleotide polymorphism (SNPs). 
In recent years, technical advances in HLA-DQ typing led to the recognition of more allelic 
variations which may be misinterpreted as HLA-DQ2 and DQ8 negative results, especially when 
only one chain (either alpha or beta) gets amplified due to variations on the other chain.  
 
HLA-DQ8 has one major haplotype while DQ2 has two major (DQ2.5 and DQ2.2) and several 
minor variant haplotypes (Table 3). The DQ8 and DQ2.5 encoded heterodimers can present gliadin 
and one copy of them is sufficient to confer risk for CD4. On the contrary, DQ2.2 alone only 
presents a different set of gliadin peptides41, 42 and when alone in heterozygous or homozygous 
forms, only rarely gives rise to CD. However, when a person has on one chromosome DQ2.2 and 
DQ7 on the other, the translated proteins formed from the alpha chain of DQ7 and the beta chain of 
DQ2.2 make up a heterodimer with almost identical amino acid sequence as in DQ2.5 individuals, 
DQ2 in trans (with current nomenclature DQ2.2/DQ7), and it is functionally equivalent to DQ2.54. 
Further variants of DQ2.2 and DQ2.3 (Table 3) also can produce functional DQ2 heterodimers43 
and this is not so uncommon as previously thought. Since the suggestion of performing HLA-DQ 
typing in EMA+ TGA+High patients to support the biopsy-sparing diagnosis, we see these variants 
more often in real CD patients. Recent advances in T cell studies demonstrated that rare cases with 
DQ9 (resembling to DQ8) also may present gliadin peptides and become coeliac42.  
 
Non-HLA predisposing genes 
About 50 SNP polymorphisms have been found to segregate in CD patients and other inflammatory 
or autoimmune disorders, such as type-1 diabetes mellitus (T1D), inflammatory bowel diseases, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8
psoriasis, asthma, etc. (see section on genetics) and predispose to a higher level of inflammation or 
more vigorous immune response to common triggers by changing expression of other genes4.  
At present, non-HLA gene results cannot be utilised in clinical diagnostics. In prospective follow up 
of risk persons, a high number of these polymorphic alleles (>13) increases the risk conferred by 
HLA-DQ alone44.    
 
Histology evaluation 
Small bowel mucosal biopsy has been so far the cornerstone for the diagnosis of CD. A distinct 
pattern of abnormalities has been observed in patients on a gluten-containing diet; the features 
include (l) partial to total villous atrophy; (2) elongated crypts; (3) increased mitotic index in the 
crypts; (4) increased intraepithelial lymphocytes (IELs); (5) infiltrations of plasma cells and 
lymphocytes as well as mast cells, eosinophils and basophils in the lamina propria; and (6) 
flattened, cuboidal epithelium. These alterations are not pathognomic of CD and most of them may 
be seen in other entities (Table 4). Hence, it is crucial to establish the gluten dependence of the 
jejunal lesion. It has now become clear that, from a pathological point of view, the small intestinal 
enteropathy in CD may be of variable severity. A spectrum of histological signs could be present. 
According to the Marsh classification45 they include 1) infiltrative lesion (more than 25 IELs /100 
epithelial cells) (Marsh 1); 2) crypt hyperplasia (Marsh 2); 3) villous atrophy of variable severity 
(Marsh 3 a, b, c). As said, these changes, even the most severe, are not pathognomonic and should 
always be interpreted in the context of the clinical and serological setting46-48. The presence of only 
infiltrative changes (Marsh 1) is non-specific (only 10% of subjects presenting this pattern is 
coeliac), but positive serology significantly increases the possibility of CD. The count of IELs at 
villous tip was reported to be more specific for CD49, 50. Among the immunohistochemical markers 
one of the best predictor of CD diagnosis is the increase of intraepithelial gamma-delta (γδ) 
lymphocytes, but the specificity of this finding is not very high51. One of the drawbacks of this 
approach is represented by the need (for the count of intraepithelial γδ+ cells) of frozen bioptic 
material embedded in OCT. The recent report of the possibility of counting γδ+ cells in paraffin 
embedded material is particularly promising in this context52. The problems related to the need of 
frozen biopsies applies also to other more recently introduced techniques, also very valuable in 
identifying coeliac patients, like the detection of intestinal deposits of IgA anti-TG2. In fact, the 
detection of such deposits by immunofluorescence has been reported to be the best marker to 
identify, among potential CD patients, those who will eventually develop a gluten dependent 
enteropathy53.  
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Lesions may be patchy54 and in a small proportion of CD patients seem only to appear in the 
duodenal bulb55. However, interpretation of the structure in bulbar biopsies may be rendered 
difficult by peptic injury and distortion by Brunner glands. Recent guidelines suggest that biopsies 
should be taken preferably during upper endoscopy from the bulb (at least one biopsy) and from the 
second or third portion of duodenum (at least four biopsies)3. Orientation is important as only a 
well oriented biopsy allows for a good evaluation of the villi/crypt ratio and a correct count of 
intraepithelial CD3+ lymphocytes56. Even with a correct orientation pathological interpretation is a 
major problem. In fact, while a good agreement has been reported for the most extreme cases 
(normal vs subtotal villous atrophy), the agreement is usually quite poor for mild intestinal lesions. 
The pathology report should include information about specimen adequacy, description of the 
orientation, the presence or not of normal villi or degree of atrophy and crypt elongation, villous-
crypt ratio, number of IELs and a grading according to Marsh-Oberhuber3. The use of a standard 
reporting format would ensure reproducibility and comparison between reports from different 
pathologists. 
 
Frontiers in diagnostic testing 
With the recognition of gluten-dependent mild intestinal lesions, tests beyond conventional 
histology have become of help in the diagnosis of CD. Immunohistochemistry to γδ+ intraepithelial 
lymphocytes and immunofluorescence to detect intestinal deposits of TGA are the most specific 
tools (see sections on biopsy). Other strategies to detect mucosal TGA can be to measure by ELISA 
antibodies released in supernatants of organ culture of small intestinal biopsies17, 57 or utilizing 
phage display libraries from biopsies and showing the biased use of the VH5 antibody gene 
family58. This method can be used for the rapid characterization of the anti-TG2 response in a 
potentially large number of subjects including asymptomatic patients whose serum antibodies may 
be undetectable. The organ culture has been advocated as a system to make diagnosis in difficult 
cases, or in cases already on a GFD which are not eligible to gluten challenge59. Another set of 
diagnostic tests is based on the demonstration of mucosal damage. Serum intestinal fatty acid 
binding protein (I-FABP) is a sensitive marker to study enterocyte damage, but it is nonspecific for 
CD60. Regenerating islet-derived 3-alpha (Reg3α) has been detected in the circulation of 91% of 
active coeliac patients and in 100% of refractory cases61. Serum Reg3α testing is useful for 
discriminating mucosal enteropathies from functional intestinal disorders. 
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It is well established that memory CD4 T cells specific for HLA-DQ2/8-gluten complexes are 
present in the small intestine of patients, but not in healthy controls. The mucosal T-cell response to 
gluten is a hallmark of the disease that has been hitherto unexploited in clinical work-up. Interferon 
(IFN)-γ-secreting T cells reactive to gluten can be detected in the peripheral blood of individuals 
with treated CD after a short consumption of wheat-containing food62.  Other strategies may be used 
to count in the blood gliadin-specific T cells. DQ2.5-glia-α1a and DQ2.5-glia-α2 tetramer+ cells 
may be visualised by flow cytometry, sorted, cloned and their specificity assessed by antigen 
stimulation63. CD4+ gluten-DQ2 tetramers increase in the peripheral blood of CD patients 
following a short gluten challenge, distinguishing them from controls, non-coeliac gluten-sensitive 
subjects and treated CD patients64.  
Recent studies have indicated that T cells specific for immunodominant gluten peptides express a 
highly biased T cell receptor (TCR) repertoire65. This TCR is characterised by the frequent presence 
of a non–germline encoded arginine residue that has a key role in mediating recognition of gliadin 
determinants presented by HLA-DQ2 or HLA-DQ8, as result of a strong selective process.  The 
presence of such TCR could represent a diagnostic tool and a predictive marker to be searched in at 
risk subjects.  
The role of HLA and non-HLA genes in the diagnostic approach to CD is discussed elsewhere.  
Recently, Galatola et al 66 reported that a small gene expression panel from peripheral blood 
monocytes could discriminate between active CD and healthy controls and according to 
multivariate discriminant analysis the expression of five genes in intestinal mucosa accounted for 
93% of the seen difference. When the same approach was applied to peripheral blood mononuclear 
cells the discriminant equation obtained allowed a correct classification of all CD cases and of 91% 
of the control samples, and, when this equation was applied to treated CD patients and to disease 
controls, a discrimination of 100%.  These observations may open the way to a new approach to the 
diagnosis of CD66. 
Diagnostic approach 
Case finding 
According to the most recent ESPGHAN diagnostic guidelines3 testing for CD should be offered to 
patients with signs of malabsorption, such as chronic diarrhoea, failure to thrive, weight loss, 
stunted growth or other signs such as delayed puberty, amenorrhoea, iron-deficiency anaemia, 
nausea or vomiting, chronic abdominal pain, cramping or distension, constipation, fatigue, recurrent 
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aphthous stomatitis, DH, fracture with inadequate traumas/ osteopenia/ osteoporosis, and abnormal 
liver biochemistry. The case finding strategy should also include subjects at risk to develop CD, 
such as individuals affected by other autoimmune or CD-associated disorders:  T1D, Down 
syndrome, autoimmune thyroiditis, Turner syndrome, Williams’s syndrome, selective IgA 
deficiency, autoimmune liver disease and first-degree relatives of CD patients. Adverse outcome of 
pregnancies, ataxia, neuropathies and other organ manifestations of unknown origin may be 
additional indications for testing in adults3,38. 
Algorithms in children and adults 
The demonstration of villous atrophy in the biopsy of the small intestine has long been considered 
the hallmark for CD together with clinical remission after withdrawal of gluten. ESPGHAN criteria 
of 19902 and other related guidelines67-69 regarded antibodies (AGA, TGA, EMA), their 
disappearance on a GFD, and HLA compatibility only ancillary and supportive of the diagnosis. 
Recently ESPGHAN has revised the criteria considering histology only one of the features of CD 
and establishing the diagnosis on a combination of symptoms, antibodies, HLA, and duodenal 
histology3. The initial approach to symptomatic patients is now to test for IgA TGA and in addition 
for total IgA in serum to exclude IgA deficiency (or as alternative using IgA TGA plus direct IgG 
DGP testing). If IgA TGA are negative and serum total IgA is normal for age (or IgG DGP 
antibodies are negative), CD is unlikely to be the cause of the symptoms. TGA+ patients should be 
referred to a paediatric gastroenterologist for further diagnostic workup, which depends on the 
serum antibody levels. TGA+ patients with antibody levels <10xULN should undergo upper 
endoscopy with multiple biopsies. Based on the evidence of a correlation between TGA+ titres and 
degree of villous atrophy, TGA+ patients with antibody levels at or >10xULN, the diagnosis of CD 
is confirmed provided that the patient is positive for EMA antibodies (EMA+TGA+High) and positive 
for DQ2 or DQ8 HLA testing. A GFD is started and the patient is followed for improvement of 
symptoms and decline of antibodies. In the rare case of negative results for HLA and/or EMA in a 
TGA+High child, the different possibilities for false-positive and false negative test results need to be 
considered (Table1-2) and the diagnostic workup should be extended including repeated testing and 
duodenal biopsies. In totally asymptomatic people belonging to high risk groups CD should always 
be diagnosed using duodenal biopsies. When biopsies are indicated, at least four fragments should 
be obtained from the descending part of the duodenum and at least one from the duodenal bulb. The 
diagnosis is confirmed by an antibody decline and preferably a clinical response to a GFD. Gluten 
challenge and repetitive biopsies will only be necessary in selected cases in which diagnostic 
uncertainty remains. The main criticisms to these guidelines are related to the variability and not 
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uniform quality of commercial kits for the measurement of TGA antibodies26. Although 
EMA+TGA+High serum antibodies are recognised to predict small bowel villous atrophy, it has been 
suggested that cut-off limits for the definitive diagnosis must be locally validated. Also other 
aspects of the algorithm, need for HLA typing and for EMA confirmation among the others need to 
be validated in already ongoing prospective studies. Further, it should be emphasised that the biopsy 
sparing diagnostic route is an option to choose when all preconditions are met as set forth in Table 
2, but there is always an option to choose histology evaluation if uncertainties in the performance of 
the actually used antibody tests or in the acceptance of the patient/parent are suspected.  
In adults the same strategy has been advocated23,30, but the majority of gastroenterologists looking 
after adults still recommend a duodenal biopsy before the diagnosis of CD68. This is advised not 
only because of the insufficient reproducibility of antibody tests, but also for the higher number of 
alternative diagnoses, sometimes very serious. Furthermore, in adults the initial biopsy could be 
more important for the follow-up, also in consideration of the possibility of lack of response to the 
GFD. However, it is an important additional point for consideration that in patient groups with high 
pre-test probability (e.g. malabsorptive symptoms) the positive predictive value of EMA+TGA+High 
results is close to 100% whereas even when taking four biopsy samples, not more than 66% of the 
patients in general will have well orientated and thus easily evaluable samples70. So the uncertainty 
of the histology evaluation compared to the serology evaluation can be higher than previously 
thought.  
In adults there is no consensus on the need of performing duodenal biopsies once a GFD is started. 
Most experts agree that subsequent biopsies are not mandatory if the patient is asymptomatic and 
has no other features suggesting risk of complications. In conclusion histology still remains 
mandatory for the diagnosis of CD in adults. However, the recent demonstration that EMA+ patients 
benefit from a GFD irrespective of symptoms and histology71 suggests that serology may become 
the main criterium for prescribing a GFD in the future. 
 
 
Clinical situations with special considerations 
 
Patients with low serum IgA level  
Selective humoral IgA deficiency (defined as total serum IgA <0.05 g/l) occurs in 1 in 500 people, 
is coupled to HLA-DQ2 background and confers elevated risk for CD (approximately 10%)8. These 
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patients only produce IgG TGA, EMA and DGP antibodies (or IgM locally in gut and in 
secretions9) when coeliac, but not IgA. Methods detecting serum IgA may have different sensitivity, 
thus it seems to be wise to search for IgG class antibodies in all patients with total serum IgA levels 
<0.2 g/l, even though some of these might not be really IgA deficient. IgA deficient and IgA 
competent CD patients do not differ either clinically or in their response to the gluten-free diet. 
However, the decrease of IgG class antibodies is much slower and high levels of IgG TGA and 
EMA positivity can persist even after 3-4 years on diet8.   
Diagnostic approach. Efficient case finding can be done by using IgA-TGA in conjunction with 
IgG DGP as the initial test when serum total IgA level is unknown. It is recommended to perform 
IgG TGA or IgG EMA determination when total serum IgA is low and/or the patient is IgG-DGP+. 
Histology evaluation at initial diagnosis is important in patients with selective IgA deficiency, even 
in EMA+TGA+High cases.  
Minimal requirements for diagnosis. Demonstration of enteropathy Marsh≥2 in conjunction with 
seropositivity for CD antibodies (preferably IgG EMA+TGA+, or at least IgG DGP+). HLA-DQ 
testing is not helpful since non-affected IgA deficient patients usually are HLA-DQ2 positive. 
Caution and pitfalls. CD may be missed if total serum IgA level is unknown and only IgA based 
test is used for initial evaluation3. It is not practical to omit initial histology evaluation in IgA 
deficient CD cases, because IgG EMA+TGA+High may persist for a long time on diet without 
measurable decrease8 and this may cast doubt on CD diagnosis. Interpretation of mild inflammatory 
duodenal changes is difficult, because they may be associated to IgA deficiency itself. 
 
Patients with other immunodeficiencies or immunosuppressive medications 
The common problems are undetectability of coeliac antibodies and a possible villous damage even 
without CD due to the immunocompromised condition itself, chronic infections or graft-versus-host 
reaction. In common variable immunodeficiency and protein-losing enteropathy both serum IgA 
and IgG levels can be very low. In CD patients with severe malabsorption or with co-morbidities 
with food allergy, Crohn’s disease, lymphangiectasia or nephrosis syndrome, the produced coeliac 
antibodies can be lost into the gut20 or urine. Also patients having previously received 
corticosteroids, azathioprine, cyclophosphamide, methotrexate, anti-TNF alpha, antitumor drugs or 
preparation for bone marrow transplantation etc. may be seronegative for a variable period of time. 
These drugs also may influence villous atrophy and may cause false negative biopsy findings.20  
 
Diagnostic approach. The emphasis is on finding some indications for TGA production either in 
the serum, gut mucosa or upon diagnostic gluten challenge when a temporary cause could be over. 
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Serum total levels of all three immunoglobulin classes should be determined. TGA antibodies may 
be detectable in the appropriate immunoglobulin class even at levels of 0.04-0.07 g/l of IgA or IgG 
or during medication with moderate doses of steroids. In autoimmune and tumour patients with 
TGA+ results, the EMA test is always recommended before proceeding to small bowel biopsy. 
When CD is suspected clinically and serum antibodies are negative, HLA-DQ typing may be 
helpful to see if the patient is at risk or not. The timing of histology evaluation may be difficult and 
both false positive and false negative results can be common and therefore it is important to save 
frozen specimens and material to extended evaluation for coeliac antibody clones by more sensitive 
molecular biology tools. In patients with secondary immunoglobulin deficiency or after drug 
withdrawal, a new search for antibodies may be rewarding.  
 
Minimal requirements for diagnosis. Demonstration of a Marsh>2 enteropathy which is clearly 
gluten dependent (when coeliac antibodies are not detectable, several biopsies and gluten challenge 
may be needed), also considering drug exposures and effects. In EMA+TGA+ patients with correct 
HLA-DQ background, CD should be considered even when histology evaluation was not 
conclusive. 
 
Caution and pitfalls. These are very difficult patient groups and often no final diagnosis can be 
reached. Serum total IgG always has to be measured when total serum IgA is <0.05 g/l. It should be 
considered, that enteropathy may improve and worsen independently of gluten and moderate villous 
damage is common in these conditions even without CD. Signs of CD and seropositivity may ’de 
novo’ appear after drug withdrawal. Whenever possible, it is advisable to screen autoimmune 
patients for CD before the immunosuppressive treatment. After bone marrow transplantation, T 
cells and HLA-DQ of the donor may determine the immune response. There are case reports both 
on the cure and transmission of CD in bone marrow transplant cases72, 73, but it is often difficult to 
prove this if the recipient had been tested either before or after the transplantation during a period 
with drugs or shortly thereafter. 
 
Extraintestinal organ damage 
Extraintestinal manifestations can be part of the malabsorptive syndrome (osteoporosis, bleeding 
disorder, amenorrhea). Other organs can be affected by TG2-specific immunglobulin (mainly IgA) 
deposition and consequent infammation74. Severe liver damage, proteinuria, haematuria, 
myocarditis, cardiomyopathy, muscular weakness, restrictive pulmonary disease, lymphadenopathy, 
brain damage or ataxia can be leading problems of CD even in the absence of gastrointestinal 
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symptoms, or even with only mild lesions in the gut. Neural manifestations have degenerative 
character and are linked to the antibody response to neural transglutaminase (TG6)38. Extraintestinal 
manifestations respond to a gluten-free diet unless irreversible loss of function has already occured. 
Diagnostic approach. In context of unexplained organ damage, case finding by antibody testing 
(TGA, EMA) is recommended, and when positive, CD diagnosis established by histological 
evaluation of the gut. Presence of TG2 (or TG6)-specific antibodies in the affected organ can be a 
proof for a direct link with CD, so when such a biopsy is planned by other indication, it is important 
to organise that a frozen specimen will be saved and made available for testing. Demonstration of 
TG2-specific IgA deposition in the gut also may be useful when villous atrophy is not present.75  
Minimal requirements for diagnosis. EMA+TGA+ results and clear clinical and/or histological 
improvement in the affected organ in response to a GFD (when the lesion is not irreversible), 
coupled with the demonstration of CD in the gut.     
Caution and pitfalls. An immunosuppressive treatment for the respective organ manifestation may 
interfere with case finding (see relevant chapter). 
 
Dermatitis herpetiformis 
DH is a special form of CD with a highly pruritic, gluten-dependent rash induced by the deposition 
of IgA in the subepidermal region and resulting inflammation. These deposits contain epidermal 
transglutaminase (TG3) and DH patients have also circulating antibodies against TG337. It is 
unclear why certain CD patients get skin symptoms, since antibodies reacting with TG3 are also 
detectable in many CD patients without rash. The same patients may have malabsorptive CD 
without rash and DH at different timepoints of their life76. Ninety-five percent of DH patients are 
positive for anti-TG2 antibodies (TGA) and EMA, 85% have villous atrophy, while the rest have 
normal villous architecture with or without TG2-associated jejunal IgA deposition22. Thus DH 
represents the full spectrum of intestinal manifestations of CD. The DH eruptions respond to the 
GFD, albeit only after a longer time (18-24 months). A symptomatic relief can be obtained by 
diaphenylsulfone or dapsone, but these drugs do not treat enteropathy77. 
Diagnostic approach. Search for serum TGA and EMA is helpful in selecting patients for skin 
biopsy. DH is diagnosed by skin immunofluorescent study from a frozen biopsy specimen taken 
from the uninvolved skin adjacent to visible lesions. A DH-specific skin biopsy result also proves 
coeliac type gluten sensitivity, regardless whether villous damage is present or not3. Histology 
evaluation of the gut mucosa is often used to demonstrate that not only the skin is involved.  
Minimal requirements for diagnosis. Skin immunofluorescent study demonstrating granular IgA 
deposition in the subepidermal region, independently from jejunal histology evaluation.  
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Caution and pitfalls. Patients with IgA deficiency cannot have DH. DH should not be regarded as a 
separate entity from CD and DH patients should be followed also by a gastroenterologist, similarly 
to CD. DH patients preferably should not be started on dapsone, because severe side effects 
(methaemoglobinaemia, kidney and liver damage) and severe flare ups after stopping the drug are 
common.   
 
Type-1 diabetes mellitus 
The risk of T1D is higher in CD both before and after CD diagnosis compared to the general 
population78, but most patients already have clinical diabetes with definitive beta cell loss before 
CD is diagnosed and thus T1D is not any more responsive to a gluten-free diet. It is unclear to 
which extent gluten and coeliac autoantibodies contribute to the damage of the pancreas. Recently 
TG2-associated IgA coeliac antibody deposition has been demonstrated in the pancreas of T1D 
patients with undiagnosed CD79.  
CD is often subclinical in T1D patients. In different studies, 3-16% of T1D cases showed TGA+ or 
EMA+TGA+ results, but antibodies are frequently present in the serum in low concentrations, may 
fluctuate and may appear during follow up and years after an earlier negative serology result. 
Thyroid and other autoimmune manifestations also develop often with time. In children with T1D, 
EMA+TGA+High serology results found by screening predicted small bowel villous atrophy 
independently of malabsorptive signs31. In T1D patients with EMA+TGA+Low or EMA-TGA+results 
villous atrophy may or may not be present or can be patchy, although inflammation markers are 
most often elevated in the duodenal mucosa.  
Diagnostic approach. T1D patients at any age are an important risk group to be screened for CD. In 
patients with EMA+TGA+High serology results, the biopsy-sparing diagnostic route may be 
considered, as endoscopy and anaesthesia need more precautions and have elevated risk in both 
children and adults with T1D. In cases with confirmed EMA+TGA+Low or EMA-TGA+ results, 
histology evaluation of the mucosa is recommended preferably with obtaining suitable samples for 
an extended evaluation (intestinal anti-TG2 deposits, morphometry, patchiness). HLA-DQ typing is 
not very helpful, as T1D itself is also associated with DQ2 and DQ8.  
Minimal requirements for diagnosis. The diagnosis of CD can be made on the basis of 
seropositivity and proven enteropathy, but a GFD may be suggested to the patient in order to 
prevent further autoimmunity even when only mild duodenal lesions are found. Although current 
ESPGHAN guidelines recommend a biopsy in asymptomatic EMA+TGA+High patients, biopsy 
sparing could be an option31, according to the patient’s willingness to accept the diagnosis without a 
histology report. 
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Caution and pitfalls. Postponing the biopsy and wait for persistent seropositivity has not been 
shown to be a safe approach as deposited antibodies and villous atrophy may persist in the gut even 
if serum antibody levels decline or turn to negative and thus the diagnosis of CD may be missed. 
T1D patients with TGA+ results at any timepoint of their life need a careful follow up if they 
continue on a gluten containing diet. The significance of isolated DGP+ results in T1D patients is 
still unclear. 
 
Patients with coeliac autoimmunity and preserved intestinal architecture - Potential coeliac 
disease 
CD has a spectrum of histological alterations, from overt intestinal atrophy up to light or absent 
signs of intestinal damage. This spectrum is particularly observed when the diagnosis is not solely 
based on the histology evaluation of the gut, but on independent variables, such as e.g. DH proven 
by skin immunofluorescent study (see relevant chapter). Similarly, coeliac gluten sensitive patients 
without villous atrophy are frequently found among those with gluten ataxia and T1D where the 
common denominator is the presence of TGA+ and/or EMA+. In the absence of other proof, TGA+ 
patients with compatible HLA but without histological abnormalities in duodenal mucosa are called 
potential CD. The patient may or may not have symptoms and signs of the disease, and, based on 
the present knowledge, may or may not develop a gluten-dependent enteropathy later on. The term 
potential is coherent with a concept of CD where the presence of enteropathy with structural 
damage is essential. This is nowadays matter of debate and the same definition ESPGHAN has 
given of CD contemplates this condition as characterised by a variable combination of features 
which include, but not necessarily, the enteropathy, then envisaging cases where the histological 
damage is missing. Furthermore, there are reports of subjects with potential CD whose symptoms 
are clearly responsive to the GFD. A dietary intervention study in EMA+ children from Finland 
showed that the disease was exacerbated in children who continued gluten consumption, whereas in 
all children who started the GFD, both the gastrointestinal symptoms and abnormal antibodies 
disappeared80. On the other hand, there are certainly cases without symptoms and others where the 
same conditions for the definition of potential CD are not consistent. A sizeable proportion of 
asymptomatic potential coeliac patients showed fluctuation or disappearance of antibody, and many 
of these, with persistent TGA+ status, did not develop mucosal damage after 9 years of follow-up81. 
We still have no good way to identify which subsets of seropositive patients will go on to develop 
villous atrophy indicating a need for therapy. In the absence of guidelines most suggest that when a 
seropositive subject does not demonstrate conclusive evidence of gluten-dependent symptoms, after 
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extended evaluation of small intestinal mucosa, should be followed up on a normal gluten-
containing diet and should be re-evaluated at regular intervals. 
 
Patients already on a gluten-free diet and challenge procedures 
Individuals with suspected but undocumented CD already adhering to a GFD cannot be accurately 
diagnosed, since they cannot be differentiated from healthy individuals. In this context, negative 
result of HLA typing may prove to be useful to (absence of HLA DQ2 or DQ8, see relevant section) 
help exclude CD.  However, the standard of care in such subjects is to perform a “gluten challenge”. 
The patient is exposed to gluten and monitored for symptoms, serology, possibly for noninvasive 
test of mucosal integrity (e.g. double sugar permeability test) and eventually for histology. Gluten 
challenge should be preceded by assessment of mucosal histology and should always be performed 
under medical supervision. Sufficient amount of gluten (around 15g/day) should be given. A recent 
study conducted in adults82 has shown significant histological, serological and symptomatic 
changes occurring already after two weeks of gluten challenge. However, it is clear that sensitivity 
to gluten exposure varies greatly between coeliac patients and some may take much longer before 
showing signs of relapse. In adults, assessment of histology should always conclude the procedure 
and titres of antibodies and/or symptoms may help in deciding the right time for biopsy. In children 
the gluten challenge should be discouraged before the age of five years and during the pubertal 
growth spurt. IgA TGA (IgG in the case of low levels of serum IgA) should be measured during the 
challenge period3. The outcome of the gluten challenge procedure is considered positive (and hence 
the diagnosis of CD confirmed) if CD specific antibodies become positive and a clinical and/or 
histological relapse is observed. In the absence of positive antibodies or symptoms the challenge 
should be considered over after two years. However, further biopsies on a normal diet are 
recommended as delayed relapse may occur later in life3.      
 
For the future improved non-invasive markers are greatly needed. They may include markers of 
mucosal deterioration, but also tests assessing the presence of gluten-specific T cells63, 64 (see 
section on frontiers). Finally, the possibility of in vitro gluten challenge on biopsy59 could avoid the 
in vivo gluten challenge and the unacceptable symptoms it may produce which render some patients 
resistant to this approach. 
 
Patients presenting at the age of less than 2 years 
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Patients in this age group have raised special concern for two order of reasons. The first, 
particularly in the past, related to possible difficulties in the differential diagnosis with other 
eneropathies, namely cow’s milk protein intolerance. That led, at the time when ESPGHAN 
guidelines underwent the first revision in 19902, to the indication of performing gluten challenge in 
every child diagnosed before the age of two years. Recent studies have shown that routine gluten 
challenge in these children has an extremely low diagnostic yield, and it is not needed when patients 
have villous atrophy in combination with EMA83, 84. The second reason of concern has been related 
to the reported lower sensitivity of TGA and EMA in this age range. Although this finding has 
commonly been reported, in fact in most studies the sensitivity for CD of such antibodies is still 
around 90% (only one out of 10 coeliacs in this age group is TGA negative)85. Nonetheless, some 
have advocated for these children the routine use of DGP tests.  
Diagnostic approach. The standard approach should be used also in this age range. The most recent 
ESPGHAN guideines suggest that, if the clincal scenario is suggestive of CD and TGA/EMA are 
negative, DGP antibodies should be implemented. In the biopsies obained from these patients it is 
still possible to look for the presence of intestinal deposits of IgA anti-TG antibodies.  
 
Minimal requirements for diagnosis. Demonstration of enteropathy Marsh≥2 in conjunction with 
seropositivity for CD antibodies (IgA EMA+TGA+, or IgG/IgA DGP+).  
 
Caution and pitfalls. In the case of presentation with gastrointestinal symptoms a careful history 
should be taken particularly to exclude the possibility of other conditions, primarily cow’s milk 
allergy. In this age range, as in any other case, there is no place for the measurement of serum AGA 
antibodies. 
 
 
Conclusions 
In recent years the role of antibody testing has increased while the role of histology has decreased in 
the diagnosis of CD, because well-controlled EMA+TGA+High serum results can non-invasively 
indicate the presence of gluten-induced enteropathy. It has also been recognised that histology 
evaluation is not helpful in a sizeable proportion of patients due to technical problems or the 
variability and slowly evolving nature of the tissue damage. However, when reliable antibody 
results cannot be achieved in a given clinical setting or locally, the priority of performing a biopsy 
remains.  
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Practice points 
• Coeliac disease may present with variable severity of symptoms and small intestinal damage 
• Patients may be detected by serologic tests 
• The final diagnosis must be confirmed by histology evaluation of the gut mucosa or (in 
symptomatic children) by the combination of HLA-DQ markers and verified 
EMA+TGA+High autoantibody results indicating gluten-induced enteropathy  
• There is no spontaneous cure; at present diagnosed patients should be advised to follow a 
lifelong gluten-free diet  
 
Research agenda 
• Natural history, predictors of deterioration and indications for treatment need to be further 
explored in subjects with coeliac autoantibodies but normal small intestinal stucture  
• In vitro methods for assessing the response to gluten should be further developed 
• There is a need for gluten non-dependent biomarkers 
• Detailed studies are necessary to assess the efficacy of non-dietary treatments 
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Table 1. Overview of diagnostic approaches at positive coeliac serology results 
Serology 
result* 
Immediate 
predictive 
value 
for villous 
atrophy 
Predictive 
value for CD 
during later 
life 
Suggested action to take Comment 
EMA+ TGA+High Close to 
100%[22-32] 
Very high Consider biopsy sparing 
diagnostic route# 
DGP does not 
add to 
diagnosis 
EMA+ TGA+Low 
 
50% or more[32, 
33] 
Very high[80] Proceed to histology 
evaluation, follow if 
Marsh<2 and not treated 
DGP does not 
add to 
diagnosis 
EMA- TGA+High Variable High, if not 
laboratory 
error 
Check for recent changes 
in gluten intake (adopted 
diet?) 
Consider non-CD 
inflammatory disorders or 
laboratory errors§ Perform 
histology evaluation and 
consider HLA-DQ typing 
CD is proven if 
histology 
Marsh≥2 
DGP+ may be 
helpful 
EMA- TGA+Low Low[32, 86] Low† Perform HLA-DQ typing. 
Consider histology 
evaluation, especially if 
family member or T1D 
DGP+ may be 
helpful 
EMA- TGA- Speaks against 
CD 
Negative† 
[20, 86]
 
Check gluten intake 
Consider non celiac gluten 
sensitivity or consider 
other cause if villous 
atrophy present (verify by 
gluten challenge 
procedure) 
Check for TGA antibodies 
in biopsy tissue‡ 
DGP+ may be 
helpful if 
villous atrophy 
present, but 
DGP+  in 
children <2 
years may be 
normal35 
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True EMA+ TGA- samples are very rare in untreated patients (mostly in the borderline range or gray 
zone), as EMA is a TGA antibody. In such cases, proceeed as with EMA+ TGA+Low cases. 
 
 
*IgA antibodies in IgA competent cases, IgG antibodies if total serum IgA is low (<0.2g/l) or the 
patient is proven to be IgA deficient (total serum IgA<0.05g/l). TGA+High if serum levels exceed 10 
times of the upper limit of normal or at cut-off predetermined by optimization study based on 
histology.  
#If clinically appropriate and additional diagnostic requirements can be met (See Husby et al3 and 
Table 2). It is not practical to omit biopsy when the patient is IgA deficient (very slow antibody 
decrease on diet). 
§Check for time interval between serology tests, consider sample mix-ups and inappropriate TGA 
cut-off, consider prozone effect at the EMA test - try to recheck with higher serum dilutions 
†Predictive value increases if deposited TG2-specific antibodies are present in the biopsy tissue 
‡Save frozen specimen at endoscopy in all cases with high clinical suspicion or malabsorption but 
negative EMA/TGA serology known before biopsy 
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 Table 2. Requirements for choosing a biopsy-sparing diagnostic option  
Obligatory 
components 
Practical requirements Comments 
Symptoms 
relevant for CD 
Symptoms or signs related to gut 
involvement and/or impaired 
absorption, DH proven by skin 
IF study. (T1D still unclear, 
some studies do support)31. 
Caution is recommended when only 
nonspecific symptoms/signs are present, 
e.g. constipation, recurrent abdominal pain 
etc. When symptoms suggest also other 
gastrointestinal disease, consider endoscopy 
and histology evaluation.  
Confirmed 
seropositivity for 
CD-specific 
antibodies 
At least two independently 
drawn blood samples positive 
It is important to exclude laboratory or 
sample handling errors and mix-ups 
EMA+TGA+High 
result 
Results by well optimized TGA 
kit and from reliable lab with 
expertise in EMA  
 
>10xULN cut-off for high TGA results in 
many commercial kits, but may need to be 
locally adjusted based on histology results. 
High DGP+ not equivalent at present. 
HLA-DQ2 or 
DQ8 background 
HLA testing available Prospective studies will tell if HLA testing 
is a significant addition in the case of 
EMA+TGA+High subjects. Practical 
importance is that an incompatible result 
may draw attention to incorrect serology 
results. In case of non-conventional alleles, 
histology is required. 
Evaluation and 
decision by a 
gastroenterologist 
Eligible patients should be 
referred to a specialist 
Before the final diagnosis gluten intake 
should not be reduced. 
Acceptance from 
the part of the 
patient/family 
 
Expert consuelling and 
preparation for a lifelong 
treatment 
In case of doubts about the diagnosis either 
by the physician or by the patient/parent 
proceed to histology evaluation. 
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Table 3. Common HLA haplotypes associated with CD 
Haplotype DQB1 
allele 
DQA1 
allele 
DRB1 
allele 
Comment Old name 
DR4-DQ8 *0302 *03(01) *04(01-
11) 
Heterodimer commonly 
presenting gliadin peptides 
DQ8 
DR3-DQ2.5 *0201 *0501 *0301 Heterodimer commonly 
presenting gliadin peptides 
DQ2 in cis or 
DR3-DQ2 
DR7-
DQ2.2[87] 
*0202 *0201 *0701 Heterodimer presenting 
different or restricted set of 
gliadin peptides[42] 
When DQB1*0202 is present 
together with DQA1*0505 
belonging to haplotype DQ7, 
functionally identical to DQ2.5 
DR7-DQ2 
 
 
DQ2 in trans 
*0303 *0201 *0701 Variant DQ2.2, often 
interpreted as DQ2 and DQ8 
negative, may have CD (rare) 
- 
DR7-DQ2.3 *0202 *0303 *0701 Similar to DQ2.2, may present 
gliadin in combination with 
DQ7, may have CD (common) 
- 
DR11-DQ7  
(DR11-
DQ7.5) 
*0301 *0505 *11(01-
04) 
Alone probably not presenting‡ 
In combination with DQ2.2, 
forms heterodimer functionally 
identical to DQ2.5[41] 
DQ7 
DR9-DQ9 *0303 *0301 *0901 Similar to DQ8, may rarely 
present gliadin[88] 
DQ9 
*0202 *0301 *0901 Similar to both DQ2.2 and 
DQ8, possible association with 
CD 
- 
 
‡CD patients only exceptionally have DQ7 alone. It is possible that in those cases the other allele is 
a variant DQ2.2 not getting amplified or misinterpreted as a non-predisposing allele.  
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Table 4. Causes of small intestinal villous atrophy other than CD 
Physical/Drug Infective Immune Inherited causes in 
enterocytes 
Mesenteric ischemia 
(pancreatic or 
duodenal 
surgery)[89] 
Chronic 
bacterial 
overgrowth 
Cow’s milk protein (rarely  
other food) enteropathies 
Eosinophilic gastroenteritis 
EpCAM mutation[90] 
(tufting enteropathy)  
Irradiation   Giardia 
lamblia 
infestation 
Crohn’s disease in small 
bowel (patchy atrophy) 
SPINT2 mutation[90] 
(tufting enteropathy plus 
keratitis, choanal atresia)  
Cytotoxic drugs, 
antitumor agents[91] 
Rotavirus 
infection 
Autoimmune enteropathy[15] MYO5B mutation[92] 
(microvillus inclusion 
disease)  
Azathioprine HIV 
enteropathy 
Graft versus host disease TTC37 mutation (tricho-
hepato-enteric syndrome 
1) 
Peptic duodenitis / 
Zollinger-Ellison 
syndrome[93]   
Whipple’s 
disease 
Rag2 mutation (Omenn 
syndrome) and other primary 
immunodeficiency conditions 
Congenital sodium 
diarrhea   
Olmesartan 
enteropathy[94, 95] 
Tropical sprue  Foxp3 mutation (IPEX 
syndrome) 
 
 
 
 
 
